Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 116

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 116
---
Item 1.        Financial Statements (Unaudited)

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets 

(Unaudited)(In thousands, except share and per share data)September 30,2025December 31,2024AssetsCurrent assets:Cash and cash equivalents$92,710 $76,247 Marketable securities860,150 817,463 Accounts receivable, net5,029 4,109 Inventory 32,034 27,616 Prepaid expenses and other current assets43,186 40,165 Total current assets1,033,109 965,600 Marketable securities304,341 638,321 Operating lease assets33,650 42,879 Property and equipment, net10,675 11,675 Other non-current assets3,930 4,724 Total assets$1,385,705 $1,663,199 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$19,553 $16,643 Accrued expenses37,217 46,861 Income taxes payable— 871 Operating lease liabilities17,987 16,781 Total current liabilities74,757 81,156 Operating lease liabilities, net of current portion26,528 40,207 Other non-current liabilities90 880 Total liabilities101,375 122,243 Stockholders’ equity:Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2025 and December 31, 2024— — Common stock, $0.001 par value; 125,000,000 shares authorized; 74,496,287 shares issued and 58,279,876 shares outstanding at September 30, 2025, and 73,372,696 shares issued and 57,156,285 shares outstanding at December 31, 202474 73 Additional paid-in capital2,538,357 2,493,811 Accumulated other comprehensive income (loss)2,051 (1,518)Treasury stock, at cost (16,216,411 shares at September 30, 2025 and December 31, 2024)(802,486)(802,486)Accumulated deficit(453,666)(148,924)Total stockholders’ equity1,